CLINICAL TRIAL SUMMARY

MDACC Study No:2011-0784 (clinicaltrials.gov NCT No: NCT01466179)
Title:An open label, multicenter, phase II study to evaluate efficacy and safety of the BiTE antibody blinatumomab in adult patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL)
Principal Investigator:Hagop Kantarjian
Treatment Agent:Blinatumomab
Study Status:Open
Study Description:The goal of this clinical research study is to learn if receiving blinatumomab
can help to control relapsed or refractory B-precursor ALL. The safety of this
drug will also be studied.

Blinatumomab is designed to bind to a defensive cell (killer cell, or T-cell)
from the body's own immune system and guiding it toward the tumor cell.
Blinatumomab can then "navigates" the immune system toward the tumor cells,
which may help to destroy them.

Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase II
Treatment Agents:Blinatumomab
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Amgen
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Hagop Kantarjian
Dept:Leukemia
For Clinical Trial Enrollment:713-792-7026
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults